Scandinavian ChemoTech (CMOTEC-B.ST) Stock Analysis & AI Equity Report
Scandinavian ChemoTech (CMOTEC-B.ST) overview
Scandinavian ChemoTech (CMOTEC-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Scandinavian ChemoTech reported revenue of SEK 12.3m and operating profit of SEK -6.3m; the year-end share price was 5.02 SEK and market capitalisation was SEK 121m. Scandinavian ChemoTech is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Scandinavian ChemoTech's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Scandinavian ChemoTech
Scandinavian ChemoTech develops and markets medical technology based on electroporation for cancer treatment in humans and animals. The company operates through Human Care and Animal Care divisions, offering systems and solutions for oncology clinics and veterinary settings. Its business is supported by commercial activity in selected international markets, including India, Southeast Asia and other regions.
Generate the Scandinavian ChemoTech report
Scandinavian ChemoTech is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Scandinavian ChemoTech and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.